Files and links (1)
Thoracic Cancer - 2025 - Youlden - Quality Indicators for Non‐Small Cell Lung Cancer in Queensland Australia 2012 2021575.94 kB
Published VersionCC BY-NC-ND V4.0, Open Access
Journal article
Quality Indicators for Non-Small Cell Lung Cancer in Queensland, Australia, 2012-2021
Thoracic Cancer, Vol.16(5), pp.1-12
2025
PMCID: PMC11896654
PMID: 40068920
Abstract
Background: Quality indicators for non-small cell lung cancer (NSCLC) have been implemented in Queensland, Australia, to assess performance across 28 elements relating to diagnosis, access, treatment, and outcomes.
Methods: Linked data were sourced from the population-based Queensland Oncology Repository. Eligible people were diagnosed with NSCLC between 2012 and 2021, with follow-up on treatment and mortality available to 31 December 2022. For each indicator, changes between 2012–2016 and 2017–2021 were assessed by fitting a multivariable Poisson regression model. Results from the models were expressed in terms of the relative likelihood (RL) using 2012–2016 as the reference period.
Results: Records were included for a total of 20 449 individuals. Significant improvements over the study period were observed for several indicators, including: review by a multidisciplinary team (RL = 1.05, 95% CI 1.03–1.07); any anticancer treatment received (RL = 1.04, 95% CI 1.03–1.06); radiation therapy for inoperable early-stage NSCLC (RL = 1.06, 95% CI 1.01–1.11); concur-rent chemo-radiotherapy for stage III disease (RL = 1.35, 95% CI 1.24–1.47); and intravenous systemic therapy (IVST) for meta-static NSCLC (RL = 1.18, 95% CI 1.13–1.22). Two-year survival from the time of surgery increased from 85% to 90% (p < 0.001). In contrast, fewer people had their performance status documented following MDT review during the latter period (RL = 0.95, 95%CI 0.94–0.96), and there was a decrease in people from rural/remote areas who received their first treatment within 30 days of diagnosis (RL = 0.89, 95% CI 0.81–0.97).
Conclusions: The endorsed suite of quality indicators offers essential benchmarking to enable ongoing monitoring of and improvement in the quality of lung cancer care in Queensland.
Details
- Title
- Quality Indicators for Non-Small Cell Lung Cancer in Queensland, Australia, 2012-2021
- Authors
- Danny R Youlden - Metro South HealthTracey Guan - Metro South HealthBryan A Chan (Corresponding Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationJasotha Sanmugarajah - Queensland HealthMargot Lehman - Princess Alexandra HospitalMorgan Windsor - Queensland HealthAlison Bolton - Queensland HealthArtika Nath - Metro South HealthNathan Dunn - Metro South HealthDanica Cossio - Metro South Health
- Publication details
- Thoracic Cancer, Vol.16(5), pp.1-12
- Publisher
- John Wiley & Sons, Inc.
- Date published
- 2025
- DOI
- 10.1111/1759-7714.70034
- ISSN
- 1759-7714; 1759-7706
- PMID
- 40068920; PMC11896654
- Copyright note
- This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.© 2025 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd.
- Grant note
- AstraZeneca Australia, D.R.Y. is funded by an unrestricted institutional educational grant.
- Organisation Unit
- Centre for Bioinnovation
- Language
- English
- Record Identifier
- 991127003202621
- Output Type
- Journal article
Metrics
4 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web Of Science research areas
- Oncology
- Respiratory System
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites